Please login to the form below

Not currently logged in
Email:
Password:

pneumococcal disease

This page shows the latest pneumococcal disease news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Prevnar-13 successor takes aim at Merck rival

Pfizer’s Prevnar-13 successor takes aim at Merck rival

Pfizer. “There continues to be a global health need to protect against the potentially devastating effects of invasive pneumococcal disease and pneumonia caused by additional serotypes, and we are dedicated to ... continue to build on our expertise in

Latest news

  • CHMP thumbs up for Novo's obesity drug Saxenda CHMP thumbs up for Novo's obesity drug Saxenda

    prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults 18 years and older. ... The vaccine is currently approved in Europe for the prevention of invasive pneumococcal disease in the same population.

  • US panel backs pneumococcal vaccines for seniors US panel backs pneumococcal vaccines for seniors

    Meanwhile, Merck said it was pleased that Pneumovax 23 would continue to play an integral role in helping to prevent pneumococcal disease in adults who are at increased risk. ... Pneumococcal disease is still a significant burden and millions of adults

  • Pfizer closes on $1bn label expansion for Prevenar Pfizer closes on $1bn label expansion for Prevenar

    The vaccine is already approved in Europe for preventing invasive pneumococcal disease in adults, a less common but more serious infection characterised by the presence of Streptococcus pneumoniae bacteria in the ... halved CAP rates, with significant

  • Pfizer acquires Baxter Men C and encephalitis vaccines for $635m Pfizer acquires Baxter Men C and encephalitis vaccines for $635m

    Susan Silbermann, president of Pfizer Vaccines, said: “For over a decade Pfizer has been the global leader in pneumococcal disease prevention. ... The company's deal with Pfizer did not include either its influenza vaccine development programme, nor

  • GSK and Pfizer extend vaccine access programme GSK and Pfizer extend vaccine access programme

    GlaxoSmithKline (GSK) and Pfizer are both working with the GAVI Alliance to provide patients in developing nations with access to their respective pneumococcal vaccines. ... GSK will provide Synflorix at a cost of $3.40 per dose up to 2024, with the

More from news
Approximately 1 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • A tailored approach to the BRIC markets A tailored approach to the BRIC markets

    In 2009, GSK signed a 1.5bn deal with the Brazilian government to provide Syflorix, its vaccine for paediatric pneumococcal disease, at around a third of the price it charged in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics